Healthcare
ImpediMed Limited (ASX:IPD)
Industry Group : Health Care Equipment & Services | Industry Group Name : Health Care Equipment & Supplies
Market Price : AUD 0.170 (0%)
(as on 2021-10-23 03:55:44)
| Previous Close | Open | Close* | Day Range | 52 WEEK HIGH LOW |
|---|---|---|---|---|
| 0.17 | 0.165 | 0.17 | 0.165L 0.175 H | 0.078L 0.19 H |
| Last Trade | 0.17 |
|---|---|
| Change% | 0.0000 |
| 52 W H/L | 0.19/0.078 |
| EBITDA | -21.373 M |
|---|---|
| NPAT After Abnormal Items | -20.706 M |
| Equity | 25.514 M |
| ROE% | -81.16% |
| Total Liabilities | 8.691 M |
|---|---|
| Total Revenue | 10.79 M |
| Cash and Cash Equivalents | 19.681 M |
Stock Information
| Share price | 0.17 |
|---|---|
| Market Cap | 254.507 M |
| Price/Gross Cash Flow | -12.29 |
| Dividend Yield Excluding Special | 0.00% |
| Ending Shares | 1.492 B | 52-Week Range | 0.078-0.19 |
| P/E ratio | 0.000 |
|---|---|
| Sector P/E | -- | EPS | -1.72 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -247.89% |
| Gross Cash Flows Per Share | -0.01 |
| Net Gearing | -75.28% |
| Gross DPS (AUD) | 0 |
|---|---|
| Gross Dividend Yield (Annualized) | 0.00% |
| Earnings Yield | 0.000 |
| Net Tangible Asset (NTA) | 0.01 |
| Sales Per Share | 0.01 |
| Book Value Per Share | 0.02 |
Announcements
About Company
A global company, ImpediMed Limited (ASX:IPD) is a world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies. These are used in the noninvasive clinical assessment and monitoring of fluid status and tissue composition.
ImpediMed was founded and is headquartered in Brisbane, Australia. Operation run in the United States and Europe.
The Company’s devices accurately and noninvasively measure a patient’s total body water, and extracellular and intracellular fluid volumes to aid in the assessment and interventions for chronic diseases.
ImpediMed, along with its subsidiaries have pioneered the use of BIS technology. The first commercially available BIS device was produced in 1990.
Notably, the Company’s L-Dex® device was the first FDA-cleared medical technology to use BIS for the assessment of lymphedema. Currently, the use of L-Dex is now recommended in clinical practice guidelines of research centers and professional organizations across the country.
In 2017, ImpediMed launched SOZO®, the world’s most advanced BIS device. It is an FDA-cleared, CE-marked and ARTG-listed digital health platform. SOZO® helps in the early detection of secondary lymphedema, offers fluid status for patients living with heart failure and enables measurement and tracking of various body composition parameters.
A single, powerful SOZO® reading allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.
The Company is exploring the use of its advanced bioimpedance technology for a wide range of commercial applications such as General health and weight management, bone content and protein-calorie malnutrition.
Corporate Information
|
|
|
|
Unit 1, 50 Parker Court, PINKENBA, QLD, AUSTRALIA, 4008
(07) 3860 3700
Dividends
| Ex-Dividend Date | Franking | DPS (AUD) | Dividend Yield |
|---|---|---|---|
| 30/06/2021 | -- | 0.000 | 0.00% |
| 30/06/2020 | -- | 0.000 | 0.00% |
| 30/06/2019 | -- | 0.000 | 0.00% |
| 30/06/2018 | -- | 0.000 | 0.00% |
| 30/06/2017 | -- | 0.000 | 0.00% |
| 30/06/2016 | -- | 0.000 | 0.00% |
| 30/06/2015 | -- | 0.000 | 0.00% |
| 30/06/2014 | -- | 0.000 | 0.00% |
| 30/06/2013 | -- | 0.000 | 0.00% |
| 30/06/2012 | -- | 0.000 | 0.00% |
Event Calendar
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Annual) | 2022-08-24 | 2022 |
| Report (Prelim) | 2022-08-24 | 2022 |
| Report (Interim) | 2022-02-21 | 2022 |
Financials
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Trading Revenue | 8.353 M | 5.694 M | 4.098 M | 4.797 M | 5.766 M |
| Other Revenue | 2.437 M | 4.189 M | 2.702 M | 3.078 M | 2.882 M |
| Total Revenue | 10.79 M | 9.883 M | 6.8 M | 7.875 M | 8.648 M |
| Interest Income | 21,000 | 39,000 | 371,000 | 428,000 | 367,000 |
| Interest Expenses | -52,000 | 0 | 0 | 0 | 0 |
| Expenses | -29.726 M | -29.815 M | -30.901 M | -34.975 M | -36.274 M |
| EBITDA | -18.936 M | -19.932 M | -24.101 M | -27.1 M | -27.626 M |
| Depreciation and Amortization | -1.7 M | -1.436 M | -682,000 | -460,000 | -272,000 |
| Depreciation | -400,000 | -461,000 | -222,000 | -353,000 | -259,000 |
| Amortisation | -1.3 M | -975,000 | -460,000 | -107,000 | -13,000 |
| EBIT | -20.636 M | -21.368 M | -24.783 M | -27.56 M | -27.898 M |
| Pre Tax Profit | -20.667 M | -21.329 M | -24.412 M | -27.132 M | -27.531 M |
| Tax Expense | -39,000 | -48,000 | -51,000 | -42,000 | -40,000 |
| Net Profit After Tax | -20.706 M | -21.377 M | -24.463 M | -27.174 M | -27.571 M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Preference Dividend | 0 | 0 | 0 | 0 | 0 |
| Net Abnormal Items | 0 | 0 | 467,000 | 0 | 0 |
| Reported Net Profit After Abnormal Items | -20.706 M | -21.377 M | -24.123 M | -27.174 M | -27.571 M |
| Ending Shares | 1.492 B | 1.002 B | 398.034 M | 397.185 M | 393.551 M |
| Weighted Average Shares | 1.202 B | 595.167 M | 397.432 M | 395.139 M | 392.685 M |
| EPS After Abnormal Items (cents) | -1.72 | -3.59 | -6.07 | -6.88 | -7.02 |
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Total Current Assets | 25.65 M | 25.45 M | 16.973 M | 37.8 M | 61.255 M |
| Total Non Current Assets | 8.555 M | 7.614 M | 5.608 M | 3.967 M | 3.088 M |
| Total Assets | 34.205 M | 33.064 M | 22.581 M | 41.767 M | 64.343 M |
| Total Current Liabilities | 8.134 M | 5.109 M | 6.661 M | 5.663 M | 5.469 M |
| Total Non Current Liabilities | 557,000 | 594,000 | 135,000 | 102,000 | 77,000 |
| Total Liabilities | 8.691 M | 5.703 M | 6.796 M | 5.765 M | 5.546 M |
| Net Assets | 25.514 M | 27.361 M | 15.785 M | 36.002 M | 58.797 M |
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Net Operating Cash | -13.258 M | -19.218 M | -19.588 M | -23.458 M | -25.566 M |
| Net Invested Cash | -2.457 M | -2.161 M | -1.765 M | -1.215 M | -362,000 |
| Net Financing Cash Flows | 16.466 M | 30.159 M | 145,000 | 256,000 | 720,000 |
| Beginning Cash | 19.663 M | 11.33 M | 31.345 M | 54.884 M | 82.254 M |
| End Cash Position | 19.681 M | 19.663 M | 11.33 M | 31.345 M | 54.884 M |
| Exchange Rate Adjustments | -733,000 | -447,000 | 1.193 M | 878,000 | -2.162 M |
| Other Cash Adjustments | 0 | 0 | 0 | 0 | 0 |
| Ending Cash | 19.681 M | 19.663 M | 11.33 M | 31.345 M | 54.884 M |
© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.